摘要
目的探究长链非编码RNA TUG1和UCA1在结肠癌组织中的表达及临床意义。方法选取2018年5月—2020年5月收治的80例结肠癌患者为研究对象,利用原位杂交与qRT-PCR法检测TUG1和UCA1的表达,对表达情况和患者病理特征及预后进行研究。结果UCA1和TUG1在结直肠癌组织表达过程中与性别、年龄以及病理情况关系较小(P>0.05),和患者肿瘤大小、是否存在淋巴结转移、疾病的分化情况以及分期情况高度相关(P<0.05)。UCA1和TUG1高表达患者肿瘤更大,淋巴结存在转移情况,分化程度较高且TNM分期以Ⅰ/Ⅱ为主;80例患者进行随访36个月,中位生存时间33.75个月,死亡人数16例,术后总生存率80.00%(64/80);Kaplan-Meier生存分析显示UCA1和TUG1高表达死亡12例,生存38例,生存率76.00%(38/50);UCA1和TUG1低表达死亡4例,生存26例,生存率86.66%(26/30)。结论直肠癌组织中lncRNA TUG1和UCA1高表达与低表达对患者疾病预后有一定影响。
Objective To investigate expression and clinical significance of long chain non coding RNAs TUG1 and UCA1 in colon cancer tissues.Methods The paper chose and reviewed 80 colon cancer patients from May 2018 to May 2020 as study objects,detected expression of TUG1 and UCA1 with in situ hybridization and qRT PCR,and studied expression status,pathological characteristics,and prognosis of patients.Results Expression of UCA1 and TUG1 in colorectal cancer tissue was not significantly correlated with gender,age,and pathological conditions(P>0.05),but was highly correlated with tumor size,lymph node metastasis,disease differentiation,and staging(P<0.05).Patients with high expression of UCA1 and TUG1 had larger tumors,lymph node metastasis,higher differentiation,and TNM staging dominated by I/Ⅱ.80 patients were followed up for 36 months,with median survival time of 33.75 months and 16 deaths.Overall postoperative survival rate was 80.00%(64/80).Kaplan Meier survival analysis showed,12 cases died and 38 cases survived due to high expression of UCA1 and TUG1,with survival rate of 76.00%(38/50).4 cases died and 26 cases survived due to low expression of UCA1 and TUG1,with survival rate of 86.66%(26/30).Conclusion High and low expression of lncRNATUG1 and UCA1 in rectal cancer tissue has some certain effect on prognosis of patients.
作者
区文弢
董栋
谢咏科
OU Wentao;DONG Dong;XIE Yongke(General Surgery Department,Nansha Hospital,Guangzhou City the First People's Hospital,Guangzhou,Guangdong 510180)
出处
《智慧健康》
2024年第17期96-98,101,共4页
Smart Healthcare
基金
广州市卫生健康科技项目《长链非编码RNA(lncRNA)EVADR在结直肠癌中的作用及机制研究》(项目编号:20181A010007)。